Lisata Therapeutics Inc banner

Lisata Therapeutics Inc
NASDAQ:LSTA

Watchlist Manager
Lisata Therapeutics Inc Logo
Lisata Therapeutics Inc
NASDAQ:LSTA
Watchlist
Price: 4.41 USD 0.46%
Market Cap: $38.9m

Lisata Therapeutics Inc
Goodwill

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

Lisata Therapeutics Inc
Goodwill Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Goodwill CAGR 3Y CAGR 5Y CAGR 10Y
Lisata Therapeutics Inc
NASDAQ:LSTA
Goodwill
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Goodwill
$35.6B
CAGR 3-Years
4%
CAGR 5-Years
-4%
CAGR 10-Years
10%
Gilead Sciences Inc
NASDAQ:GILD
Goodwill
$8.3B
CAGR 3-Years
0%
CAGR 5-Years
1%
CAGR 10-Years
22%
Amgen Inc
NASDAQ:AMGN
Goodwill
$18.7B
CAGR 3-Years
6%
CAGR 5-Years
5%
CAGR 10-Years
2%
Astria Therapeutics Inc
NASDAQ:ATXS
Goodwill
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Goodwill
$1.5B
CAGR 3-Years
12%
CAGR 5-Years
9%
CAGR 10-Years
41%
No Stocks Found

Lisata Therapeutics Inc
Glance View

Market Cap
38.9m USD
Industry
Biotechnology

Lisata Therapeutics Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Basking Ridge, New Jersey and currently employs 27 full-time employees. Lisata Therapeutics, Inc., formerly Caladrius Biosciences, Inc., is a clinical-stage biopharmaceutical company. The firm is engaged in the discovery, development, and commercialization of therapies for the treatment of advanced solid tumors and other major diseases. The firm focuses primarily on advancing its CendR Platform technology product candidates in a range of oncology indications. Its lead investigational product candidate, LSTA1, is designed to modify the tumor microenvironment by activating an uptake pathway that allows anti-cancer drugs to penetrate solid tumors. LSTA1 actuates an active transport system in a tumor-specific manner, resulting in systemically co-administered anti-cancer drugs penetrating and accumulating in the tumor, while normal tissues are not affected. In addition, the Company also has clinical development programs based on its autologous CD34+ cell therapy technology platform.

LSTA Intrinsic Value
2.27 USD
Overvaluation 49%
Intrinsic Value
Price

See Also

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett